Abstract
Ornithine transcarbamylase (OTCase) deficiency, the most commoninherited urea cycle disorder, is transmitted as an X-linked trait. The clinical phenotype in affected males as well as heterozygous females shows a spectrum of severity ranging from neonatal hyperammonaemic coma to asymptomatic adults. The ornithine transcarbamylase enzyme is a trimer with three active sites per holoenzyme molecule, each of which is composed of an interdomain region of one polypeptide and a polar domain of the adjacent polypeptide. The OTC gene is located on the short arm of the X-chromosome and one of the two alleles undergoes inactivation in female cells. Approximately 140 mutations have been found in families affected with OTCase deficiency, most having their own 'private' mutation. Large deletions of one exon or more are seen in approximately 7% of patients, small deletions or insertions are seen in about 9%, and the remaining mutations are single base substitutions. Approximately 15% of mutations affect RNA splicing sites. The recurrent mutations are distributed equally among CpG dinucleotide hot spots. Generally, mutations causing neonatal disease affect amino acid residues that are 'buried' in the interior of the enzyme, especially around the active site, while those associated with late onset and milder phenotypes tend to be located on the surface of the protein. Very few mutations have been found in the sequence of the leader peptide, proportionally much fewer than in the sequence of the mature enzyme. Only few of the mutations have been expressed in bacteria or mammalian cells for the study of their deleterious mechanisms. Examples of expressed mutations include R277W and R277Q associated with late-onset disease, which markedly increase the Km for ornithine, shift the pH optimum to more alkaline and decrease the thermal stability of the purified mutant enzyme. R141Q (neonatal disease) disrupts the active site, whereas the purified R40H mutant has normal catalytic function and this mutation is likely to affect posttranslational processing such as mitochondrial targeting. It appears that most new mutations occur in male sperm and are then passed on to a transmitting heterozygous female. Uncommonly, mild mutations are transmitted by asymptomatic males to their daughters, subsequently resulting in clinical disease of males in future generations. The causes for variable expressivity of these mutations are currently unknown but are likely to involve a combination of environmental and genetic modifiers.
Similar content being viewed by others
REFERENCES
Brusilow SW, Horwich AL (1995) Urea cycle enzymes. In Scriver R, Beaudet AL, Sly WS, Valle D, eds. The Molecular and Metabolic Bases of Inherited Disease, 7th edn. New York: McGraw-Hill, 1187-1232.
Ha, Y, McCann MT, Tuchman M, Allewell NM (1997) Substrate induced conformational change in a trimeric ornithine transcarbamoylase. Proc Natl Acad Sci USA 94: 9550-9555.
Honzatko RB, Crawford JL, Monaco HL, et al (1982) Crystal and molelcular structures of native and CTP ligated aspartate carbamoyltransferase from Esherichia coli. J Mol Biol 160: 219-263.
Maddalena A, Edward SJ, O'Brien WE, Nussbaum RL (1988) Characterization of point mutations in the same arginine codon in three unrelated patients with ornithine trans-carbamylase deficiency. J Clin Invest 82: 1353-1358.
Morizono H, Tuchman M, Rajagopal BS, et al (1997a) Expression, purification and kinetic characterization of wild type human ornithine transcarbamylase and a recurrent mutant that produces.'late onset' hyperammonemia. Biochem J 322: 625-631.
Morizono H, Listrom CD, Rajagopal BS, et al (1997b) Late onset ornithine transcarbamylase deficiency: function of three purified recombinant mutant enzymes. Hum Mol Genet 6: 963-968.
Morsy MA, Zhao JZ, Ngo TT, et al (1996) Patient selection may affect gene therapy success. Dominant negative effects observed for ornithine transcarbamylase in mouse and human hepatocytes. J Clin Invest 97: 826-832.
Schneider TD, Stephens RM (1990) Sequence logos: a new way to display consensus sequences. Nucleic Acids Res 18: 6097-6100.
Shapiro MB, Senapathy P (1987) RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. Nucleic Acid Res 15: 7155-7175.
Suess PJ, Tsai MY, Holzknecht RA, Horowitz M, Tuchman M (1992) Screening for gene deletions and known mutations in 13 patients with ornithine transcarbamylase deficiency. Biochem Med Metab Biol 47: 250-259.
Tuchman M, Holzknecht RA, Gueron AB, Berry SA, Tsai MY (1992) Six new mutations in the ornithine transcarbamylase gene detected by single-strand conformation polymor-phism. Pediatr Res 32: 600-604.
Tuchman M, Plante RJ, McCann MT, Qureshi AA (1994) Seven new mutations in the human ornithine transcarbamylase gene. Hum Mutat 4: 57-60.
Tuchman M, Morizono H, Reish O, Yuan X, Allewell NM (1995) The molecular basis of ornithine transcarbamylase deficiency: modelling the human enzyme and the effects of mutations. J Med Genet 32: 680-688.
Tuchman M, Plante RJ, Garcia-Perez MA, Rubio V (1996) Relative frequency of mutations causing ornithine transcarbamylase deficiency in 78 families. Hum Genet 97: 274-276.
Villeret V, Tricot C, Stalon V, Dideberg O (1995) Crystal structure of Pseudomonas aerugin-osa catabolic ornithine transcarbamylase at resolution: a different oligomeric organization in the transcarbamoylase family. Proc Natl Acad Sci USA 92: 10762-10766.
Rights and permissions
About this article
Cite this article
Tuchman, M., Morizono, H., Rajagopal, B.S. et al. The biochemical and molecular spectrum of ornithine transcarbamylase deficiency. J Inherit Metab Dis 21 (Suppl 1), 40–58 (1998). https://doi.org/10.1023/A:1005353407220
Issue Date:
DOI: https://doi.org/10.1023/A:1005353407220